13. 多発性硬化症/視神経脊髄炎
[臨床試験数:3,050,薬物数:2,147(DrugBank:348),標的遺伝子数:244,標的パスウェイ数:228

Searched query = "Multiple sclerosis/Neuromyelitis optica", "Multiple sclerosis", "Neuromyelitis optica", "MS", "NMOSD", "Devic disease", "Balo concentric sclerosis", "Baló concentric sclerosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03161028
(ClinicalTrials.gov)
July 1, 201818/5/2017Lipoic Acid for Progressive Multiple Sclerosis (MS)Lipoic Acid for the Treatment of Progressive Multiple SclerosisMultiple SclerosisDrug: Lipoic acid;Drug: PlaceboVA Office of Research and DevelopmentNULLRecruiting18 Years70 YearsAll118Phase 2United States;Canada
2NCT03493841
(ClinicalTrials.gov)
June 8, 201821/3/2018Comparing Tolerability and Absorption of Racemic and R-lipoic Acid in Progressive Multiple SclerosisComparing Gastrointestinal Tolerability and Absorption of Racemic Lipoic Acid and R-lipoic Acid in Progressive Multiple Sclerosis: a Randomized Crossover TrialMultiple Sclerosis;Progressive Multiple Sclerosis;Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple SclerosisDrug: Alpha Lipoic AcidRebecca SpainNULLCompleted18 YearsN/AAll20Phase 1United States
3NCT02133664
(ClinicalTrials.gov)
June 20146/5/2014Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple SclerosisLipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple SclerosisMultiple Sclerosis;CognitionDrug: lipoic acid and omega-3 fatty acids;Drug: PlaceboOregon Health and Science UniversityNational Multiple Sclerosis SocietyCompleted18 Years65 YearsAll54Phase 1;Phase 2United States
4NCT01381354
(ClinicalTrials.gov)
October 201026/5/2011Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)Nutrition, Neuromuscular Electrical Stimulation (NMES) and Secondary Progressive Multiple Sclerosis (SPMS)Multiple SclerosisOther: Progressive exercise;Device: Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV;Other: Modified paleolithic diet;Dietary Supplement: Omega 3 fatty acids;Dietary Supplement: Full Spectrum vitamin;Dietary Supplement: Essential - hydroxytyrosol;Dietary Supplement: Maltodextrin fiber supplement;Dietary Supplement: Mineral boost (magnesium);Dietary Supplement: Niacinamide;Dietary Supplement: Methyl B12;Dietary Supplement: Taurine;Dietary Supplement: creatine;Dietary Supplement: thiamine;Dietary Supplement: riboflavin;Dietary Supplement: N acetylcysteine;Dietary Supplement: alpha lipoic acid;Dietary Supplement: L acetyl carnitine;Dietary Supplement: methyl folate;Dietary Supplement: coenzyme Q;Behavioral: meditation;Behavioral: self massage;Behavioral: learning;Dietary Supplement: Coconut oilUniversity of IowaDirect MS Canada;DJO Incorporated;Pinnaclife Inc.;TZ Press, LLCCompleted18 Years65 YearsAll38Phase 1United States
5NCT01188811
(ClinicalTrials.gov)
October 201025/8/2010Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS)Lipoic Acid for Neuroprotection in Secondary Progressive MSMultiple Sclerosis, Chronic ProgressiveDrug: lipoic acid;Drug: PlaceboVA Office of Research and DevelopmentOregon Health and Science UniversityCompleted40 Years70 YearsAll54Phase 2;Phase 3United States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT00997438
(ClinicalTrials.gov)
August 201016/10/2009Defining the Anti-inflammatory Role of Lipoic Acid in Multiple SclerosisDefining the Anti-inflammatory Role of Lipoic Acid in Multiple SclerosisMultiple SclerosisDietary Supplement: Lipoic AcidPortland VA Medical CenterOregon Health and Science UniversityCompleted18 YearsN/AAll69Phase 1United States
7NCT00676156
(ClinicalTrials.gov)
December 20057/5/2008A Study of the Pharmacokinetics and Immunologic Effects of Lipoic Acid in Multiple SclerosisA Pilot Trial to Study the Pharmacokinetics of Oral Lipoic Acid (LA) and Immunological Effects of LA in Multiple SclerosisMultiple SclerosisDrug: oral lipoic acid (LA);Drug: lipoic acid (LA) with fish oil and LA without fish oil;Drug: R lipoic acidOregon Health and Science UniversityNational Center for Complementary and Integrative Health (NCCIH)Completed18 Years80 YearsBoth40Phase 1United States
8NCT00010842
(ClinicalTrials.gov)
September 19992/2/2001Natural Antioxidants in the Treatment of Multiple SclerosisNatural Antioxidants in the Treatment of Multiple SclerosisMultiple SclerosisDrug: Ginkgo biloba;Drug: Alpha-lipoic acid;Drug: Vitamin E/Selenium;Drug: Essential fatty acidsNational Center for Complementary and Integrative Health (NCCIH)NULLCompletedN/AN/ABothPhase 1;Phase 2United States